Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.59 |
| ▸ | NPY1R | P25929 | 6/20 | 0.59 |
| ▸ | NPY2R | P49146 | 5/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863542 | 0.94 | OPRD1 (0.58) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL29365670 | 0.89 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL30656945 | 0.89 | NPY4R (0.57) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL9822809 | 0.89 | FOLH1 (0.69) | NPY4RNPY1RNPY2ROPRD1FOLH1 | |
| SCHEMBL14940816 | 0.89 | FOLH1 (0.69) | NPY4RNPY1RNPY2ROPRD1FOLH1 | |
| SCHEMBL29532240 | 0.89 | FOLH1 (0.69) | NPY4RNPY1RNPY2ROPRD1FOLH1 | |
| Hydrochloric Acid SCHEMBL30698091 | 0.88 | FOLH1 (0.67) | NPY4RNPY1RNPY2ROPRD1FOLH1 | |
| SCHEMBL5552838 | 0.88 | FCER2 (0.48) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL12038997 | 0.88 | LTA4H (0.62) | — | |
| SCHEMBL12057953 | 0.88 | LTA4H (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190883-A1 | STABLE PEPTIDES HAVING RENALASE AGONIST ACTIVITY | PERSONAL THERAPEUTICS, LLC | 2023-06-22 | — | — | US | claimed |
| EP-4157307-A2 | STABLE PEPTIDES HAVING RENALASE AGONIST ACTIVITY | Bessor Pharma, LLC (US) | 2023-04-05 | — | — | EP | claimed |
| WO-2025034944-A9 | METHODS AND COMPOSITIONS FOR PROLONGED RENALASE AGONIST ACTIVITY | YALE UNIVERSITY (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025034944-A1 | METHODS AND COMPOSITIONS FOR PROLONGED RENALASE AGONIST ACTIVITY | YALE UNIVERSITY (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20230190883-A1 | STABLE PEPTIDES HAVING RENALASE AGONIST ACTIVITY | PERSONAL THERAPEUTICS, LLC | 2023-06-22 | — | — | US | disclosed |
| EP-2927241-A1 | TDF-related compounds and analogs thereof | Thrasos Innovation, Inc. (CA) | 2015-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190883-A1 | STABLE PEPTIDES HAVING RENALASE AGONIST ACTIVITY | TMPRSS2, ANPEP, ACE2 | NPY4R 2033/4885NPY1R 928/4885NPY2R 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.